NCT00714454已完成不适用
5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris: A Double-Blind, Placebo Controlled Trial
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
12-week study to compare the efficacy and safety of a course of a twice daily treatment with APS in the form of a lotion to its vehicle for the treatment of acne.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 39 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subject has read, understood, and signed appropriate informed consent, photo consent, and HIPAA consent in their own language.
- •Subject has visible mild to severe acne, as assessed by the investigator.
- •Subject will be available and willing to return for follow-up visits.
- •Subject agrees not to use any other acne treatment products during the study.
- •Subject is otherwise healthy, non-febrile, and is not suffering from an infection likely to require antibiotic therapy during the study period.
- •Subject or guardian must be able to understand the new HIPAA regulations and sign the HIPAA form.
- •Subject is between the ages of 18 and
- •Subject agrees and understands that APS or its vehicle is to be applied to the subject twice daily for 12 weeks; no other topical or systemic medication affecting the course of acne and/or evaluability is to be used during the study.
- •Subject agrees to use only the cleanser, moisturizer with sunscreen, and treatment provided by the study site for the duration of the study.
- •Subject understands and agrees that he/she can not be treated with a systemic antibiotic for acne during the study.
- •Subject agrees he/she will not use an acne topical treatment for two weeks prior to Day 0.
排除标准
- •Subject or guardian has not signed informed consent, photo consent or HIPAA form.
- •Subject is suffering from a condition likely to require medical attention, including administration of oral or systemic antibiotics, oral or systemic corticosteroids, or any other treatment which in the opinion of the investigator could influence the results of the study.
- •Subject is pregnant or lactating.
- •Subject is suffering from an abnormal skin condition not usually associated with acne.
- •Subject will not be available for follow-up visits.
- •Subject has been previously enrolled in any clinical study in which treatment was received within the past 30 days.
- •Subjects without comedones, papules, pustules, or nodules.
- •Subject has a history of hypersensitivity to any other ingredients of the study lotion.
- •Subject has a history of anaphylaxis.
- •Subject is not able to avoid excessive sun exposure.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
3 期
A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine FibroidsMetrorrhagiaLeiomyomaMenorrhagiaNCT00160381Abbott432
已完成
3 期
Treatment of Uterine Fibroids With Asoprisnil(J867)MetrorrhagiaMenorrhagiaLeiomyomaNCT00152269Abbott475
已完成
2 期
A Study to Evaluate the Effects of Asoprisnil(J867) in Women With Uterine Fibroids Who Are Scheduled for a HysterectomyUterine FibroidsLeiomyomaNCT00150644Abbott33
已完成
2 期
A Long-Term Study to Evaluate the Safety of Asoprisnil in the Treatment of Women With Endometriosis From Study M01-398EndometriosisNCT00160420Abbott73
已完成
2 期
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe PsoriasisPsoriasisNCT01096862Astellas Pharma Inc124